# HPV 16 and 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9 to 14 years compared with three doses of quadrivalent vaccine in women aged 18 to 25 years in Costa Rica (PRIMAVERA)

Source: https://onco.cc/key-papers/paper-cortes-primavera-single-dose-hpv-lancet-infect-dis-2025/  
OnCo record `paper-cortes-primavera-single-dose-hpv-lancet-infect-dis-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In Guanacaste, one dose of the bivalent HPV vaccine in 620 girls gave antibody levels non-inferior to three quadrivalent doses in women for HPV 18 but not HPV 16, though almost every girl had antibodies to both after three years.

## Summary

A non-randomised, open-label immunobridging trial in Guanacaste Province (NCT03728881) that gave one dose of bivalent HPV vaccine to girls aged 9 to 14 and three doses of quadrivalent vaccine to women aged 18 to 25, and compared antibody concentrations at 36 months, to support a single-dose indication for the bivalent vaccine. Funded by the National Cancer Institute, Cancer Research UK and the Gates Foundation.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: Lancet Infectious Diseases
- Year: 2025
- DOI: 10.1016/S1473-3099(25)00284-1
- Authors: Cortés B, Ocampo R, Porras C, Liu D, et al.
- Findings: 620 girls and 620 women were enrolled between April and August 2019.; At 36 months the HPV 16 antibody ratio was 0.50 (96% CI 0.44 to 0.57), not non-inferior; the HPV 18 ratio was 1.11 (96% CI 0.95 to 1.29), non-inferior.; 99.8% of girls were seropositive for HPV 16 and 98.9% for HPV 18.
- What it means: Antibody levels alone did not meet the bar for changing the vaccine's label to one dose, which is why trials measuring protection directly, such as ESCUDDO, were needed.
- Caveats: Not randomised, and it measures antibodies rather than protection from infection.

## Sources

- DOI: https://doi.org/10.1016/S1473-3099(25)00284-1
- PubMed: https://pubmed.ncbi.nlm.nih.gov/40683285/

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [HPV bivalent vaccine (types 16 and 18)](https://onco.cc/drugs/hpv-bivalent-vaccine/)
- institutions: [Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN)](https://onco.cc/institutions/acib-funin-costa-rica/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)

---
JSON: https://onco.cc/api/v1/entities/paper-cortes-primavera-single-dose-hpv-lancet-infect-dis-2025.json